Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Andreas A. Argyriou, Dimos-Dimitrios Mitsikostas, Elisa Mantovani, Michail Vikelis & Stefano Tamburin. (2021) Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. Expert Review of Neurotherapeutics 21:8, pages 923-944.
Read now
Read now
Cristina Tassorelli, Gioacchino Tedeschi, P Sarchielli, Luigi Alberto Pini, Licia Grazzi, Pierangelo Geppetti, Marina De Tommaso, Marco Aguggia, P Cortelli & Paolo Martelletti. (2018) Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics 18:2, pages 167-176.
Read now
Read now
Articles from other publishers (24)
David García-Azorín, Blanca Martínez, María Gutiérrez, Marina Ruiz-Piñero, Ana Echavarría, Álvaro Sierra & Ángel L. Guerrero. (2022) Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study. Toxins 14:12, pages 850.
Crossref
Crossref
Corinna Börner, Tabea Renner, Florian Trepte-Freisleder, Giada Urban, Paul Schandelmaier, Magdalena Lang, Matthias F. Lechner, Helene Koenig, Birgit Klose, Lucia Albers, Sandro M. Krieg, Thomas Baum, Florian Heinen, Mirjam N. Landgraf, Nico Sollmann & Michaela V. Bonfert. (2022) Response Predictors of Repetitive Neuromuscular Magnetic Stimulation in the Preventive Treatment of Episodic Migraine. Frontiers in Neurology 13.
Crossref
Crossref
Nailah Asif, Apurva Patel, Deepanjali Vedantam, Devyani S Poman & Lakshya Motwani. (2022) Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment. Cureus.
Crossref
Crossref
Helia Hemasian, Faezeh Abedini, Arman Arab & Fariborz Khorvash. (2022) A novel technique of botulinum toxin injection around skull sutures for chronic migraine: A randomized controlled clinical trial. Journal of Research in Medical Sciences 27:1, pages 85.
Crossref
Crossref
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Sabina Cevoli, Bruno Colombo, Massimo Filippi, Fabio Frediani, Francesco Bono, Licia Grazzi, Antonio Salerno, Bruno Mercuri, Antonio Carnevale, Claudia Altamura & Fabrizio Vernieri. (2020) Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study. Headache: The Journal of Head and Face Pain 61:2, pages 363-372.
Crossref
Crossref
Diana Obelieniene, Ruta Pestininkaite & Daiva Rastenyte. 2020. Migraine. Migraine.
Valentina Orlando, Sara Mucherino, Valeria Marina Monetti, Ugo Trama & Enrica Menditto. (2020) Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study. BMJ Open 10:11, pages e038972.
Crossref
Crossref
Clara Domínguez Vivero, Yago Leira, Marta Saavedra Piñeiro, Xiana Rodríguez-Osorio, Pedro Ramos-Cabrer, Carmen Villalba Martín, Tomás Sobrino, Francisco Campos, José Castillo & Rogelio Leira. (2020) Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine. Toxins 12:8, pages 479.
Crossref
Crossref
Ivan Urits, Gavin Clark, Daniel An, Bredan Wesp, Rebecca Zhou, Ariunzaya Amgalan, Amnon A. Berger, Hisham Kassem, Anh L. Ngo, Alan D. Kaye, Rachel J. Kaye, Elyse M. Cornett & Omar Viswanath. (2020) An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain and Therapy 9:1, pages 195-215.
Crossref
Crossref
Galina Vorobeychik, Denise Black, Paul Cooper & Ashley Cox. (2020) Multiple sclerosis and related challenges to young women's health: Canadian expert review. Neurodegenerative Disease Management 10:2s, pages 1-13.
Crossref
Crossref
Patrizia Ferroni, Piero Barbanti, Antonella Spila, Federica Fratangeli, Cinzia Aurilia, Luisa Fofi, Gabriella Egeo & Fiorella Guadagni. (2019) Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine. Current Medicinal Chemistry 26:34, pages 6191-6206.
Crossref
Crossref
Elio Clemente Agostoni, Piero Barbanti, Paolo Calabresi, Bruno Colombo, Pietro Cortelli, Fabio Frediani, Pietrangelo Geppetti, Licia Grazzi, Massimo Leone, Paolo Martelletti, Luigi Alberto Pini, Maria Pia Prudenzano, Paola Sarchielli, Gioacchino Tedeschi & Antonio Russo. (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. The Journal of Headache and Pain 20:1.
Crossref
Crossref
Carlo Piccinni, Sabina Cevoli, Giulia Ronconi, Letizia Dondi, Silvia Calabria, Antonella Pedrini, Immacolata Esposito, Valentina Favoni, Giulia Pierangeli, Pietro Cortelli & Nello Martini. (2019) A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. The Journal of Headache and Pain 20:1.
Crossref
Crossref
David García-Azorín, Javier Trigo-López, Álvaro Sierra, Laura Blanco-García, Enrique Martínez-Pías, Blanca Martínez, Blanca Talavera & Ángel L Guerrero. (2019) Observational, open-label, non-randomized study on the efficacy of onabotulinumtoxinA in the treatment of nummular headache: The pre-numabot study. Cephalalgia 39:14, pages 1818-1826.
Crossref
Crossref
Piero Barbanti, Gabriella Egeo & Dimos D. Mitsikostas. (2019) Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number?. Headache: The Journal of Head and Face Pain 59:9, pages 1659-1661.
Crossref
Crossref
Sonia Quintas, David García-Azorín, Patricia Heredia, Blanca Talavera, Ana Beatriz Gago-Veiga & Ángel L Guerrero. (2019) Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients. Pain Medicine 20:9, pages 1815-1821.
Crossref
Crossref
Lorena Dima, Andreea Bălan, Marius Alexandru Moga, Cătălina Georgeta Dinu, Oana Gabriela Dimienescu, Ioana Varga & Andrea Elena Neculau. (2019) Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines. Toxins 11:8, pages 465.
Crossref
Crossref
Fernando KOWACS, Célia Aparecida de Paula ROESLER, Élcio Juliato PIOVESAN, Elder Machado SARMENTO, Henrique Carneiro de CAMPOS, Jayme Antunes MACIEL JR, Leandro Cortoni CALIA, Liselotte Menke BAREA, Marcelo Cedrinho CICIARELLI, Marcelo Moraes VALENÇA, Maria Eduarda Nobre de Magalhães COSTA, Mário Fernando Prieto PERES, Pedro André KOWACS, Pedro Augusto Sampaio ROCHA-FILHO, Raimundo Pereira da SILVA-NÉTO, Thais Rodrigues VILLA & Mauro Eduardo JURNO. (2019) Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arquivos de Neuro-Psiquiatria 77:7, pages 509-520.
Crossref
Crossref
Brin Freund & Aruna Rao. (2019) Efficacy of Botulinum Toxin in Tension‐Type Headaches: A Systematic Review of the Literature. Pain Practice 19:5, pages 541-551.
Crossref
Crossref
Piero Barbanti, Luisa Fofi, Cinzia Aurilia & Gabriella Egeo. (2019) Does the migraine attack start in the cortex and is the cortex critical in the migraine process?. Neurological Sciences 40:S1, pages 31-37.
Crossref
Crossref
Piero Barbanti, L. Fofi, S. Cevoli, P. Torelli, C. Aurilia, G. Egeo, L. Grazzi, D. D’Amico, G. C. Manzoni, P. Cortelli, F. Infarinato & N. Vanacore. (2018) Establishment of an Italian chronic migraine database: a multicenter pilot study. Neurological Sciences 39:5, pages 933-937.
Crossref
Crossref
C. Domínguez, P. Pozo-Rosich, Y. Leira & R. Leira. (2018) Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxin A. European Journal of Neurology 25:4, pages e48-e48.
Crossref
Crossref
Farhat Husain, Gabriel Pardo & Meheroz Rabadi. (2018) Headache and Its Management in Patients With Multiple Sclerosis. Current Treatment Options in Neurology 20:4.
Crossref
Crossref
P. Barbanti & G. Egeo. (2018) Predictors of response to onabotulinumtoxin A in chronic migraine. European Journal of Neurology 25:3.
Crossref
Crossref